Clinical TrialsLorundrostat demonstrated a superior hypertension profile, showing significant and clinically meaningful blood pressure reductions across subgroups with increased risk for poor cardiovascular outcomes.
Financial StrategyThe closing of an upsized $287.5M underwritten public offering of common stock, along with existing cash, supports pre-commercialization activities for lorundrostat and its ongoing clinical development.
Market PositionLorundrostat is positioned for differentiated advancement based on its demonstrated superior hypertension profile compared to AstraZeneca's baxdrostat.